Alpha 2.0
Login Register
» Authors » Dianna L Shipley

Dianna L Shipley

Explore the profile of Dianna L Shipley including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 307
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
Gastroenterology
Top 10 Co-Authors
John D Hainsworth
F Anthony Greco
David R Spigel
Howard A Burris 3rd
David M Waterhouse
Dana S Thompson
Robert C Whorf
Victor G Gian
John D Zubkus
Suzanne F Jones
Published In
Lung Cancer
J Clin Oncol
Cancer
Oncologist
Oncology (Williston Park)
Affiliations
Soon will be listed here.
Recent Articles
1.
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial
Spigel D, Shipley D, Waterhouse D, Jones S, Ward P, Shih K, et al.
Oncologist . 2019 Aug; 24(12):e1409-e1416. PMID: 31420467
Background: This randomized, double-blinded, phase II trial evaluated the efficacy of carboplatin and pemetrexed plus either apatorsen, an antisense oligonucleotide targeting heat shock protein (Hsp) 27 mRNA, or placebo in...
2.
Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium
Spigel D, Hainsworth J, Shipley D, Mekhail T, Zubkus J, Waterhouse D, et al.
Lung Cancer . 2018 Mar; 117:38-43. PMID: 29496254
Purpose: First-line treatment for patients with extensive-stage small cell lung cancer (SCLC) includes treatment with platinum-based combination chemotherapy. Amrubicin is a synthetic anthracycline with single-agent activity in relapsed/refractory SCLC. In...
3.
Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2
Spigel D, Hainsworth J, Joseph M, Shipley D, Hagan M, Thompson D, et al.
Cancer . 2018 Feb; 124(9):1982-1991. PMID: 29451696
Background: The best treatment for patients with advanced non-small cell lung cancer (NSCLC) and a poor performance status is not well defined. In this phase 2 trial, patients were randomized...
4.
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)
Spigel D, Rubin M, Gian V, Shipley D, Burris 3rd H, Kosloff R, et al.
Lung Cancer . 2017 Nov; 113:79-84. PMID: 29110854
Purpose: To evaluate the efficacy of erlotinib, continued after tumor progression, plus sorafenib versus sorafenib alone in patients with refractory metastatic non-small cell lung cancer (NSCLC) who previously benefitted from...
5.
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
Ko A, Murphy P, Peyton J, Shipley D, Al-Hazzouri A, Rodriguez F, et al.
Oncologist . 2017 Sep; 22(12):1427-e129. PMID: 28935773
Lessons Learned: The addition of the heat shock protein 27 (Hsp27)-targeting antisense oligonucleotide, apatorsen, to a standard first-line chemotherapy regimen did not result in improved survival in unselected patients with...
6.
Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer
Yardley D, Shipley D, Peacock N, Shastry M, Midha R, Priego V, et al.
Breast Cancer Res Treat . 2015 Jul; 152(3):557-67. PMID: 26155975
The purpose of the study is to evaluate the feasibility and efficacy of adding sunitinib to paclitaxel/carboplatin in the neoadjuvant therapy of patients with triple-negative breast cancer (TNBC). Patients had...
7.
High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium
Hainsworth J, Shipley D, Reeves Jr J, Arrowsmith E, Barnes E, Waterhouse D
Clin Genitourin Cancer . 2013 May; 11(3):283-289.e1. PMID: 23684421
Background: The dose of bevacizumab necessary to optimally inhibit tumor angiogenesis in advanced renal cell carcinoma is unknown. In this phase II trial, we evaluated the efficacy and safety of...
8.
Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium
Hainsworth J, Waterhouse D, Penley W, Shipley D, Thompson D, Webb C, et al.
Cancer Invest . 2013 Apr; 31(5):323-9. PMID: 23614653
Purpose: To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC). Methods: Patients with advanced RCC and ≤ 1 previous targeted therapy were treated. Results:...
9.
Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer
Spigel D, Greco F, Waterhouse D, Shipley D, Zubkus J, Bury M, et al.
Lung Cancer . 2012 Sep; 78(1):70-5. PMID: 22947511
Background: Epothilones, a new class of cytotoxic agents, have demonstrated activity in non-small-cell lung cancer (NSCLC). This phase II study examined ixabepilone/carboplatin (cohort A) and ixabepilone/carboplatin/bevacizumab (cohort B) as first-line...
10.
Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium
Hainsworth J, Spigel D, Greco F, Shipley D, Peyton J, Rubin M, et al.
Cancer J . 2011 Sep; 17(5):267-72. PMID: 21952273
Purpose: : The aim of the study was to evaluate the feasibility and efficacy of adding bevacizumab and erlotinib to concurrent chemoradiation therapy for first-line treatment of patients with locally...